Corcept Therapeutics (CORT) Stock Price, News & Analysis

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CORT shares.
View CORT analyst ratings or view top-rated stocks.

4 brokers have issued 1 year target prices for Corcept Therapeutics' shares. Their CORT share price targets range from $28.00 to $47.50. On average, they predict the company's stock price to reach $37.30 in the next year. This suggests a possible upside of 62.2% from the stock's current price.
View analysts price targets for CORT or view top-rated stocks among Wall Street analysts.

Corcept Therapeutics' stock was trading at $32.48 at the start of the year. Since then, CORT stock has decreased by 29.2% and is now trading at $23.00.
View the best growth stocks for 2024 here.

Corcept Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 21,330,000 shares, an increase of 5.5% from the March 15th total of 20,220,000 shares. Based on an average daily volume of 1,420,000 shares, the short-interest ratio is currently 15.0 days. Currently, 23.9% of the company's shares are short sold.
View Corcept Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our CORT earnings forecast.

Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its quarterly earnings results on Thursday, February, 15th. The biotechnology company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.25 by $0.03. The biotechnology company had revenue of $135.41 million for the quarter, compared to the consensus estimate of $129.27 million. Corcept Therapeutics had a net margin of 21.86% and a trailing twelve-month return on equity of 21.98%. The company's quarterly revenue was up 31.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.14 earnings per share.

ETFs with the largest weight of Corcept Therapeutics (NASDAQ:CORT) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), Janus Henderson Small Cap Growth Alpha ETF (JSML), Invesco S&P SmallCap Health Care ETF (PSCH), ALPS Medical Breakthroughs ETF (SBIO), ETC 6 Meridian Small Cap Equity ETF (SIXS) and iShares U.S. Pharmaceuticals ETF (IHE).

Corcept Therapeutics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $600.0 million-$630.0 million, compared to the consensus revenue estimate of $531.6 million.

6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), Xtrackers California Municipal Bond ETF (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).

Corcept Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.05%), Los Angeles Capital Management LLC (0.05%), Evanson Asset Management LLC (0.02%), Clearview Wealth Advisors LLC (0.01%), Sound Income Strategies LLC (0.00%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Daniel N Swisher Jr, Daniel N Swisher, Jr, David L Mahoney, G Leonard Baker, Jr, Gary Charles Robb, Hazel Hunt, Joseph Douglas Lyon, Joseph K Belanoff, Sean Maduck and William Guyer.
View institutional ownership trends.

Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.